Orthocell (ASX:OCC) - Managing Director, Paul Anderson
Managing Director, Paul Anderson
Source: Business News
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Orthocell (OCC) sees its final patient complete their 12-month follow-up visit as part of a tendon regeneration study
  • The company’s rotator cuff tendon study assessed the effectiveness of Ortho-ATI, Orthocell’s tendon regeneration treatment, compared to injectable corticosteroids as a non-surgical treatment
  • Orthocell says if its study objectives are met it will be able to progress its commercialisation strategy to deliver the first FDA-approved, injectable cell therapy for treating chronic tendon injuries
  • The company says it remains on track to complete its analysis of the study, with data expected to be available in Q4 2021
  • Orthocell last traded at 46.5 cents on August 30

Orthocell (OCC) has seen its final patient complete their 12-month follow-up visit as part of its tendon regeneration study.

The rotator cuff tendon study was designed to assess the effectiveness of Ortho-ATI, Orthocell’s tendon regeneration treatment, compared to injectable corticosteroids as a non-surgical treatment.

Orthocell said if it meets its study objectives, it will be the first of its kind. The company says this could place it in a strong position to progress its US commercialisation strategy to deliver the first FDA-approved, injectable cell therapy in orthopaedics for the treatment of chronic tendon injuries.

“We are delighted to have completed the 12-month follow-up of the last patient treated in this highly focused, randomised controlled study,” Orthocell Managing Director Paul Anderson said.

“This is an important development milestone for Ortho-ATI and the company, representing the first randomised controlled trial for a tendon cell therapy to be completed for this indication globally.”

According to the company, shoulder pain is the third most common reason to visit a doctor for a chronic muscloskeletal condition, with around five million patients said to suffer from rotator cuff tendinopathy per year in the US alone.

Currently, there are no long-term, non-surgical solutions available to repair chronic shoulder tendon injuries. While treatment options like physical therapy, anti-inflammatory drugs and injectables are available, these may only provide short-term paid relief, and surgery can be very expensive.

Orthocell said its Ortho-ATI addresses these demands by offering accelerated regeneration of injured tendons, directly addressing the underlying cause of injury and replenishing degenerative tissue with healthy mature tendon cells.

The company says its treatment has been shown to support patients in their return to recreational activities, the workplace and competitive sports, with Ortho-ATI receiving previous clinical validation in clinical data published up to 4.5 years post treatment in peer-reviewed journals.

The company says it remains on track to complete its analysis of the study, with data expected to be available in Q4 2021.

Orthocell last traded at 46.5 cents on August 30.

OCC by the numbers
More From The Market Herald

" Race Oncology (ASX:RAC) reports $1.8m in cash outflows

Race Oncology (ASX:RAC) reports $1.8 million in cash outflows
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…
Fiji Kava (ASZ:FIJ) - CEO and Managing Director, Dr Anthony Noble

" Fiji Kava (ASX:FIJ) hits quarterly revenue record

Fiji Kava (ASX:FIJ) has tabled a record quarterly revenue of $476,531 for the December quarter, up…